{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:13:55Z","timestamp":1791292435340,"version":"4.1.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Triazole resistant A. fumigatus has been documented in many parts of the world. In the Netherlands, incidence is now above 10% and results in the need for long-term parenteral therapy with liposomal amphotericin B (LAmB). The long terminal half-life of LAmB suggests that intermittent dosing could be effective, making the application of outpatient antifungal therapy (OPAT) possible. Here, we report our experience with the use of OPAT for Invasive Fungal Infections (IFI). All adult patients treated with LAmB with a 2 or 3 times weekly administration via the outpatient departments in four academic tertiary care centers in the Netherlands and Belgium since January 2010 were included in our analysis. Patient characteristics were collected, as well as information about diagnostics, therapy dose and duration, toxicity, treatment history and outcome of the IFI. In total, 18 patients were included. The most frequently used regimen (67%) was 5\u00a0mg\/kg 3 times weekly. A partial response to the daily treatment prior to discharge was confirmed by CT-scan in 17 (94%) of patients. A favorable outcome was achieved in 13 (72%) patients. Decrease in renal function occurred in 10 (56%) cases but was reversible in all and was treatment limiting in one patient only. The 100-day mortality and 1-year mortality after initiation of OPAT were 0% and 6%, respectively. In a selected population, and after confirmation of initial response to treatment, our data support the use of OPAT with LAmB for treatment of IFI in an intermittent dosing regimen.<\/jats:p>","DOI":"10.1093\/mmy\/myz134","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T12:10:11Z","timestamp":1576843811000},"page":"874-880","source":"Crossref","is-referenced-by-count":13,"title":["Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B"],"prefix":"10.1093","volume":"58","author":[{"given":"Robert J","family":"van de Peppel","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands"},{"name":"Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Schauwvlieghe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Infectious Diseases, Erasmus MC, University Medical Center Rotterdam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Van Daele","sequence":"additional","affiliation":[{"name":"Pharmacy Department, University Hospitals Leuven and Department of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Pharmacotherapy, KU Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Spriet","sequence":"additional","affiliation":[{"name":"Pharmacy Department, University Hospitals Leuven and Department of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Pharmacotherapy, KU Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan W","family":"van't Wout","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J","family":"Br\u00fcggemann","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Radboud Institute for Health Sciences, Radboud University Medical Center; Center of Expertise in Mycology Radboud \/ CWZ, Radboud University Medical Center Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J A","family":"Rijnders","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Infectious Diseases, Erasmus MC, University Medical Center Rotterdam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J C","family":"Hendriks","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G J","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,1,21]]},"reference":[{"key":"2020101609551200200_bib1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020101609551200200_bib2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40506-014-0016-2","article-title":"Treatment options in invasive aspergillosis","volume":"6","author":"Panackal","year":"2014","journal-title":"Curr Treat Options Infect Dis"},{"key":"2020101609551200200_bib3","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/14740338.2017.1273900","article-title":"An update on the safety and interactions of antifungal drugs in stem cell transplant recipients","volume":"16","author":"Girmenia","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"2020101609551200200_bib4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"2020101609551200200_bib5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/cid\/ciu911","article-title":"Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group","volume":"60","author":"Herbrecht","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020101609551200200_bib6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QCO.0000000000000005","article-title":"Azole resistance in Aspergillus fumigatus","volume":"26","author":"Vermeulen","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"2020101609551200200_bib7","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3201\/eid2106.140717","article-title":"Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus","volume":"21","author":"van der Linden","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2020101609551200200_bib8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3389\/fmicb.2015.00428","article-title":"Prevalence and mechanism of triazole resistance in Aspergillus fumigatus in a referral chest hospital in Delhi, India and an update of the situation in Asia","volume":"6","author":"Chowdhary","year":"2015","journal-title":"Front Microbiol."},{"key":"2020101609551200200_bib9","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/jac\/dku566","article-title":"Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany","volume":"70","author":"Steinmann","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020101609551200200_bib10","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3201\/eid1905.130075","article-title":"Azole-resistant Aspergillus fumigatus, Iran","volume":"19","author":"Seyedmousavi","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"2020101609551200200_bib11","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.cmi.2018.11.027","article-title":"Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management","volume":"25","author":"Lestrade","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2020101609551200200_bib12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","article-title":"International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus","volume":"21","author":"Verweij","year":"2015","journal-title":"Drug Resist Updat"},{"key":"2020101609551200200_bib13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cncr.11510","article-title":"Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection","volume":"98","author":"Nucci","year":"2003","journal-title":"Cancer"},{"key":"2020101609551200200_bib14","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1086\/599105","article-title":"Recent advances in the management of mucormycosis: from bench to bedside","volume":"48","author":"Spellberg","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020101609551200200_bib15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2710.2001.00380.x","article-title":"Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance and cost","volume":"26","author":"Bernard","year":"2001","journal-title":"J Clin Pharm Ther"},{"key":"2020101609551200200_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/cid\/cix733","article-title":"Rates of and risk factors for adverse drug events in outpatient parenteral antimicrobial therapy","volume":"66","author":"Keller","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020101609551200200_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/00365548.2014.967290","article-title":"A national survey of infectious disease practitioners on their use of outpatient parenteral antimicrobial therapy (OPAT)","volume":"47","author":"Muldoon","year":"2015","journal-title":"Infect Dis (Lond)"},{"key":"2020101609551200200_bib18","doi-asserted-by":"crossref","first-page":"e00010","DOI":"10.1128\/CMR.00010-19","article-title":"Extended dosing regimens for fungal prophylaxis","volume":"32","author":"Lehrnbecher","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"2020101609551200200_bib19","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1093\/cid\/ciz064","article-title":"Preclinical safety, tolerability, pharmacokinetics, pharmacodynamics, and antifungal activity of liposomal amphotericin B","volume":"68","author":"Adler-Moore","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020101609551200200_bib20","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1093\/cid\/ciz076","article-title":"Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B","volume":"68","author":"Groll","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020101609551200200_bib21"},{"key":"2020101609551200200_bib22","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1093\/cid\/ciz091","article-title":"Pharmacology of liposomal amphotericin B: an introduction to preclinical and clinical advances for treatment of life-threatening invasive fungal infections","volume":"68","author":"Walsh","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020101609551200200_bib23","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/jac\/dkh460","article-title":"Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis","volume":"54","author":"Adler-Moore","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2020101609551200200_bib24","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/jac\/dkm077","article-title":"Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B","volume":"59","author":"Smith","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2020101609551200200_bib25","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","article-title":"Liposomal amphotericin B (AmBisome[R]): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions","volume":"76","author":"Stone","year":"2016","journal-title":"Drugs"},{"key":"2020101609551200200_bib26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijantimicag.2007.10.001","article-title":"Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study","volume":"31","author":"Cordonnier","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"2020101609551200200_bib27","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1592\/phco.25.5.690.63591","article-title":"Experience with community-based amphotericin B infusion therapy","volume":"25","author":"Malani","year":"2005","journal-title":"Pharmacotherapy"},{"key":"2020101609551200200_bib28","article-title":"Official website of the Dutch Belgian Mycoses Study Group"},{"key":"2020101609551200200_bib29","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020101609551200200_bib30","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S1473-3099(09)70265-8","article-title":"Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?","volume":"9","author":"Verweij","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"2020101609551200200_bib31","doi-asserted-by":"crossref","first-page":"570.e1","DOI":"10.1016\/j.cmi.2016.04.001","article-title":"Azole-resistant Aspergillus fumigatus in Denmark: a laboratory-based study on resistance mechanisms and genotypes","volume":"22","author":"Jensen","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2020101609551200200_bib32","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ijantimicag.2018.10.021","article-title":"Managing invasive aspergillosis in haematological patients in the era of resistance polymerase chain reaction and increasing triazole resistance: a modelling study of different strategies","volume":"53","author":"van de Peppel","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2020101609551200200_bib33","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/TP.0000000000000393","article-title":"High-dose weekly liposomal amphotericin B antifungal prophylaxis in patients undergoing liver transplantation","volume":"99","author":"Giannella","year":"2015","journal-title":"Transplantation"},{"key":"2020101609551200200_bib34","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/jac\/30.4.535","article-title":"Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neotropenic patients","volume":"30","author":"Moreau","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"2020101609551200200_bib35","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/bmj.317.7155.379","article-title":"Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study","volume":"317","author":"Schoffski","year":"1998","journal-title":"BMJ"},{"key":"2020101609551200200_bib36","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/00003246-199608000-00007","article-title":"Administration of amphotericin B in lipid emulsion decreases nephrotoxicity","volume":"24","author":"Sorkine","year":"1996","journal-title":"Crit Care Med"},{"key":"2020101609551200200_bib37","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jiac.2018.04.014","article-title":"The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B","volume":"24","author":"Kato","year":"2018","journal-title":"J Infect Chemother"},{"key":"2020101609551200200_bib38","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/myc.12585","article-title":"Efficacy and safety of amphotericin B lipid-based formulations: a systematic review and meta-analysis","volume":"60","author":"Steimbach","year":"2017","journal-title":"Mycoses"},{"key":"2020101609551200200_bib39","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/jphp.12802","article-title":"Efficacy and safety of amphotericin B formulations: a network meta-analysis and a multicriteria decision analysis","volume":"69","author":"Tonin","year":"2017","journal-title":"J Pharm Pharmacol"},{"key":"2020101609551200200_bib40","doi-asserted-by":"crossref","first-page":"8629891","DOI":"10.1155\/2019\/8629891","article-title":"Renal recovery following liposomal amphotericin B-Induced nephrotoxicity","volume":"2019","author":"Personett","year":"2019","journal-title":"Int J Nephrol"},{"key":"2020101609551200200_bib41","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jac\/dkt402","article-title":"Risk factors for nephrotoxicity in patients receiving outpatient continuous infusions of vancomycin in an Australian tertiary hospital","volume":"69","author":"Norton","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2020101609551200200_bib42","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ijantimicag.2009.07.011","article-title":"Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy","volume":"34","author":"Ingram","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"2020101609551200200_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciy867","article-title":"2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy","volume":"68","author":"Norris","year":"2019","journal-title":"Clin Infect Dis"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/58\/7\/874\/33902484\/myz134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/58\/7\/874\/33902484\/myz134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T13:55:31Z","timestamp":1602856531000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/58\/7\/874\/5713420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,21]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,1,21]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myz134","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,1,21]]}}}